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Abstract The human amyloid precursor-like protein 2
(APLP2) is a member of the Alzheimer’s disease amyloid
precursor protein (APP) gene family. The human APLP2
ectodomain (sAPLP2) was expressed in the yeast Pichia pastoris
and the recombinant sAPLP2 was purified from the culture
medium in a single step by metal-chelating Sepharose chromato-
graphy. The neuritotrophic activity of APLP2 was compared to
the APP isoforms sAPP695 and sAPP751 on chick sympathetic
neurones. APLP2 had neurite outgrowth-promoting activity
similar to that of the APP isoforms. This suggests that APP
and APLP2 have a similar or related role and supports the idea
of a redundancy in function between the APP-gene family
proteins.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Alzheimer’s disease (AD) is the most common cause of
dementia in the elderly. The pathology of AD is characterised
by the presence of cortical and cerebrovascular amyloid de-
posits and intracellular neuro¢brillary tangles [1]. Extracellu-
lar deposits of amyloid have been shown to consist predom-
inantly of aggregates of a 39^43-residue polypeptide AL [2,3].
AL is derived by proteolytic cleavage from the larger amyloid
precursor protein (APP) [4]. APP is part of a gene family,
which contains the APP-like proteins (APLP) 1 and 2 [5^
10]. At the amino acid level APLP2 has the greatest homology
to APP (52% identical and 71% similar) compared with
APLP1 which is 42% identical and 64% similar to APP.
APLP2 shows conservation of all 12 cysteine residues in the
amino-terminus and the putative zinc-, copper- and heparin-
binding domains, the putative mitogenic RERMS domain, the
Kunitz-protease inhibitor domain (KPI), and the cytoplasmic
clathrin/talin-binding domain [7,8,10]. The region of weakest
homology between APP and both APLP1 and APLP2 occurs
near the transmembrane domain. In APP, this region includes
the AL domain, but APLP1 and APLP2 both lack a region
homologous to AL and are therefore considered to be non-
amyloidogenic proteins.
APLP2 and APP share a similar pattern of expression in
both human and mouse [7,10,11]. APLP2 is present in human
brain and cerebrospinal £uid as well as in the supernatant
fractions of primary and clonal cultures [11]. This suggests
that APLP2 and APP may be processed via a similar mecha-
nism that is capable of yielding secreted species that are C-
terminally truncated. In the mouse, APLP2 is detected in all
tissues at comparable levels [7], while APLP1 expression is
restricted to the brain where it has been found to be expressed
in neuronal post-synaptic densities [12]. Neural-speci¢c local-
isation of APLP1 may imply a specialised function for this
protein and thus explain its lower homology to APP and
APLP2.
The function of APP remains essentially unknown. APP
knockout (APP3/3) mice have been shown to carry a dis-
crete, non-lethal phenotype [13]. In vitro studies have shown
that primary hippocampal cultures from APP3/3 mice have
reduced viability and retarded neurite outgrowth [14] suggest-
ing a role for APP in cell viability and neuritogenesis. In
contrast, there was no di¡erence in susceptibility to AL tox-
icity or oxidative stress between primary cortical and cerebel-
lar neurones derived from APP3/3 and normal mice [15]. An
APLP2 knockout (APLP23/3) mouse with a deleted exon 1
also appeared phenotypically normal [16]. However, when
APLP23/3 and APP3/3 mice were crossed to generate
APP/APLP2 double knockout mice they showed a reduction
in viability with only a 26% survival rate [16]. This indicates
APP and APLP2 are required for post-natal survival. The
high degree of homology between APP and APLP2 and the
lack of a clear phenotype in the APP3/3 and APLP23/3
mice or the APP3/3 neurones under oxidative stress predicts
a shared or overlapping function. However, there are cur-
rently few data to show that APLP and APP have similar
activities.
In this study we investigated the ability of recombinant
APLP2 to stimulate neurite outgrowth from chick sympa-
thetic neurones. A number of studies have shown that APP
has neuritogenic activity on a range of neuronal types [17^21].
We show that APLP2 has similar neurite outgrowth-promot-
ing activity to that of APP.
2. Materials and methods
2.1. Antibodies
Mouse monoclonal antibody 22C11 reacts against an epitope
present at the N-terminus of both APP and APLP2 [7,22] and was
obtained from Boehringer Mannheim.
2.2. Pichia pastoris expression construct
Polymerase chain reaction (PCR) was used to amplify a 1998-bp
DNA fragment corresponding to residues 28^693 of human APLP2
(with the KPI domain). Human APLP2 cDNA [10] was used as the
PCR template (gift of Drs. Wilma Wasco and Rudolph Tanzi (MIT,
Cambridge, MA, USA)). The following oligonucleotide primers were
used at a ¢nal concentration of 1 pmol: CCG AAT TCT TGG CGC
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TGG CCG GCT ACA and CCC CTC TAG ATC AAC TGC TAC
TCA GAC TGA AGT C. The pPIC9-sAPLP2 construct was con-
¢rmed by sequence analysis. The pPIC9-sAPLP2 plasmid DNA was
linearised with SalI and electroporated into electrocompetent P. pas-
toris GS115 or the protease mutant strains SMD1163, 1165, 1168 [23].
The sAPPK constructs have been previously described [23].
2.3. Expression and puri¢cation of sAPLP2 and sAPPK by immobilised
copper-chelating chromatography
APLP2-expressing clones were identi¢ed by Western blotting cul-
ture supernatants with 22C11 as previously described [23]. The highest
expressing clones for GS115 and the SMD strains were used for sub-
sequent expression.
Large-scale expression and puri¢cation was performed in 200-ml
cultures in a 1-l ba¥ed £ask. Cultures were induced for 24 h. The
yeast supernatant fraction was harvested by centrifugation and phe-
nylmethylsulphonyl £uoride (0.1 mg/ml) was added to inhibit proteol-
ysis. The supernatant fraction was ¢ltered through a 0.2-Wm ¢lter
(Millipore). A 5-ml HiTrap Chelating Sepharose column (Amersham
Pharmacia Biotech) was washed with 5 ml of double-distilled water
and then loaded with 0.5 ml of 0.1 M CuSO4. The column was
washed again with 5 ml of double-distilled water to remove unbound
salts and equilibrated with 5 ml of start bu¡er (0.02 M sodium phos-
phate, 0.5 M NaCl, pH 7.2). The ¢ltered yeast supernatant was loaded
onto the column using a peristaltic pump (Amersham Pharmacia Bio-
tech) at a £ow rate of 3 ml/min. The column was washed with 5 ml of
start bu¡er to remove unbound material. Bound protein was eluted
from the column by stripping the copper from the Sepharose matrix
with 5 ml of start bu¡er containing 0.05 M EDTA. The eluted protein
was desalted using a PD-10 Sephadex G-25 M Column (Amersham
Pharmacia Biotech) into 50 mM Tris-HCl bu¡er, pH 8 or phosphate-
bu¡ered saline.
2.4. SDS-polyacrylamide gel electrophoresis, immunodetection and
silver staining
Sodium dodecyl sulphate-polyacrylamide electrophoresis (SDS-
PAGE) and Western blotting were performed as described previously
[23]. SDS-polyacrylamide gels were silver-stained using a silver stain-
ing kit (Bio-Rad).
2.5. Neurite outgrowth assay
Neurite outgrowth assays were performed as previously described
[24]. Brie£y, 24-well cell culture plates were coated with 0.1 mg/ml
polylysine for 1 h, wells were washed with sterile distilled water and
then coated with proteins of interest. Proteins were used at a concen-
tration of 10 Wg/ml. Each well was rinsed with phosphate-bu¡ered
saline following a 2 h incubation, and 1U104 cells isolated from 12-
day-old chick sympathetic ganglia were added. Cultures were grown
for 24 h, then ¢xed with 2.5% (v/v) glutaraldehyde in phosphate-bu¡-
ered saline. Computer-assisted image analysis was used to determine
neurite length in nine separate ¢elds within the centre of each well.
Four wells per treatment group were examined and at least 120 cells
were counted for each treatment group. Di¡erences between groups
were analysed by a two-tailed Student’s t-test.
3. Results
3.1. Expression of sAPLP2 in P. pastoris
The APLP2 ectodomain (sAPLP2) from amino acids 23^
693 [10] was expressed in P. pastoris using the vector pIC9 in
frame with the Saccharomyces cerevisiae prepro K-factor sig-
nal peptide. The pPIC9-sAPLP2 plasmid was transfected into
P. pastoris strain GS115 and the protease mutant strains
SMD1163 (pep4), SMD1165 (pep4, prb1) and SMD1168
(prb1). The pep4 and prb1 genes correspond to the vacuolar
proteases proteinase A and proteinase B respectively. These
protease mutant strains may reduce proteolysis of recombi-
nant proteins and hence improve protein expression [25^27].
The culture medium from the four di¡erent sAPLP2-P.
pastoris strains were screened by SDS-PAGE and Western
blotting with the anti-APP/APLP2 monoclonal antibody
22C11. A major immunoreactive band migrating at 100^110
kDa corresponding to the expected size of sAPLP2 was de-
tected, as well as a number of minor breakdown products
(Fig. 1). No immunoreactive bands were seen in supernatant
fractions from cells expressing the pIC9 vector alone. There
were no signi¢cant di¡erences in the breakdown pattern be-
tween the di¡erent strains. Di¡erences in expression levels
were observed between clones and are consistent with our
previous work expressing sAPP in P. pastoris [23]. The clones
yielding the highest immunoreactivity were selected for subse-
quent analysis.
3.2. Puri¢cation of sAPLP2 by copper-chelating
chromatography
The ectodomains of both APP and APLP2 have been
shown to bind to copper [28]. This copper-binding property
was utilised in a single-step puri¢cation protocol using immo-
bilised copper-chelating chromatography [29]. The superna-
tant fractions from the GS115 and the SMD clones were
loaded directly on to a copper-charged chelating Sepharose
column and non-speci¢c proteins washed away. Bound
sAPLP2 was eluted from the column with bu¡er containing
0.05 M EDTA. A Western blot of a typical puri¢cation pro¢le
of sAPLP2 from GS115 is shown (Fig. 1). There was a large
enrichment of the recombinant sAPLP2 as seen by the in-
crease in immunoreactivity in the eluted fractions (Fig. 1,
lane 9). The ¢nal puri¢ed sAPLP2 from the four di¡erent
P. pastoris strains following bu¡er exchange and concentra-
tion was analysed by silver staining and Western blotting (Fig.
1b). The sAPLP2 doublet was the predominant protein seen
by silver staining (Fig. 1b) and all silver-staining bands were
recognised by the 22C11 antibody (Fig. 1b). The breakdown
products were a minor component of the puri¢ed protein. The
FEBS 21380 4-1-99
Fig. 1. Puri¢cation of sAPLP2 expressed in GS115 on copper-che-
lating Sepharose chromatography. a: 5-Wl aliquots of the starting
material (lane 1), £ow-through (lane 2), wash (lane 3), 1-ml eluate
fractions (lanes 4^9) and molecular weight standards (lane 4). The
gel was Western-blotted and probed with 22C11. b: SDS-PAGE
analysis of the puri¢ed sAPLP2 following bu¡er exchange and con-
centration. Silver stain (left-hand panel) and Western blot with
22C11 (right-hand panel) of sAPLP2 expressed in GS115,
SMD1163, SMD1165 and SMD1168. Positions of the molecular
weight standards (M) are indicated.
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nature of the doublet is not clear, but it may represent di¡er-
ent glycosylation isoforms. The yield of puri¢ed sAPLP2 was
approximately 40 mg/l for all the strains. No proteins were
puri¢ed from the supernatant of a pIC9 vector-alone control
culture as determined by silver staining and Western blotting
(data not shown). The sAPP695K and sAPP751K proteins (the
ectodomains of the APP isoforms 695 and 751 ending at the
K-secretase site [23]) were also puri¢ed by copper-chelating
Sepharose chromatography.
3.3. Neurite outgrowth assay
A number of activities have been proposed for APP includ-
ing modulation of neurite outgrowth [30]. To determine if this
activity is conserved in APLP2, we tested the neuritogenic
activity of the recombinant sAPLP2 and compared this to
recombinant sAPPK. Substrate-bound sAPLP2, sAPP695K
and sAPP751K all stimulated neurite outgrowth from chick
sympathetic neurones compared to cells cultured on polyly-
sine alone (Fig. 2). All three proteins demonstrated an in-
crease in the number of neurites per neurone compared with
polylysine alone, but less than the laminin-stimulated cultures
(Fig. 3a). There was no di¡erence in activity between sAPLP2
and sAPPK. Analysis of neurite length showed that the out-
growth stimulated by sAPLP2 was signi¢cantly di¡erent from
sAPPK. Neurites which were exposed to sAPLP2 generated
neurites which were 70% and 47% longer than sAPP695K
and sAPP751K respectively (Fig. 3b).
4. Discussion
In this study we used the P. pastoris yeast expression system
to overexpress the ectodomain of human APLP2. The single-
step puri¢cation protocol which utilised the endogenous ami-
no-terminal metal-binding sites [28,31] simpli¢ed the previous
multi-step puri¢cation schemes [23,32,33] with no obvious re-
duction in purity. Expression of APLP2 in the SMD vacuolar
protease mutant strains did not improve the expression pro-
¢le. A similar result was obtained for sAPPK expressed in
these strains [23] and indicates the proteolysis of APP and
APLP2 in P. pastoris was not due to these vacuolar proteases.
This study shows that like sAPP, sAPLP2 is able to stim-
ulate neurite outgrowth, both in number of neurones with
neurites and in neurite length. We conclude that the neurite-
promoting activity is shared by other members of the APP
family. The neuritotrophic activity of APP can be modulated
by heparan sulphate proteoglycans with di¡erent proteogly-
cans having contrasting e¡ects [24,34]. While APLP2 can bind
to heparin in a similar manner to APP [35], it remains to be
determined if it is also modulated by heparan sulphate pro-
teoglycans and how this relates to APP. The retarded neurite
development of APP3/3 hippocampal neurones [14] and the
¢nding that sAPLP2 has greater neurite length-promoting ac-
tivity than sAPPK suggests APP and APLP2 have distinct
roles in controlling neurite development. Therefore, studying
the activities of the APLP molecules and how they relate to
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Fig. 3. E¡ect of substrate-bound sAPLP2, sAPP695K and
sAPP751K on chick sympathetic neurones. a: Number of neurones
with neurites. Values are means þ S.E.M. Signi¢cantly di¡erent from
polylysine (P6 0.05) as assessed by a Student’s t-test. b: Neurite
length. Values are means þ S.E.M. *Signi¢cantly di¡erent from
sAPP695K and sAPP751K (P6 0.05) as assessed by a Student’s
t-test.
Fig. 2. Phase-contrast micrographs of 12-day embryonic chick sympathetic neurones cultured on substrate-bound (a) polylysine, (b) polylysine
and laminin, (c) polylysine and sAPLP2, (d) polylysine and sAPP751K. Bar 20 Wm.
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APP is important in understanding the function of the APP
family in AD.
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